We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Roche Diagnostics

Develops, manufactures, and markets a wide range of in vitro diagnostic systems, instruments, reagents, and tests read more Featured Products: More products

Download Mobile App




Latest Generation Coagulation Monitor Boasts Built-in WI-FI Connectivity

By LabMedica International staff writers
Posted on 13 Dec 2015
A new coagulation monitor for professional use combines two critical assays—the activated partial thromboplastin time (aPTT) test and the prothrombin time (PT) test—in a single small, portable instrument.

The medical equipment manufacturer Roche (Basel, Switzerland) recently announced the launch of the CoaguChek Pro II system in countries accepting the CE marking for diagnostic tools. More...
CoaguChek Pro II combines two tests in a single device for greater insight into patients’ coagulation status in acute care settings, such as emergency rooms, operating rooms, intensive care units, or anticoagulation clinics.

The instrument is small and portable, requiring only a small sample volume of eight microliters to run a full test, and accepts different blood sample types, including capillary blood from a finger prick as well as venous and arterial whole blood. Accuracy and precision of the test strips are guaranteed, since each lot of the test strips is precalibrated against the World Health Organization (WHO) reference method.

The instrument boasts built-in WI-FI connectivity, which allows test results to be transmitted automatically in real time to patients’ electronic health records, ensuring that vital information is immediately available at every point of care.

“Building on the best in class quality, CoaguChek Pro II is small, light, and convenient with accuracy and precision that our customers have come to expect from CoaguChek over the past 20 years,” said Jean-Claude Gottraux, head of professional diagnostics at Roche. “As the latest addition to the CoaguChek family, CoaguChek Pro II expands our coagulation point of care offering beyond self-monitoring and doctors’ offices to also include more specialized settings such as the ER and OR.”

Related Links:

Roche



New
Gold Member
Automatic Hematology Analyzer
CF9600
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
New
Urine Analyzer
respons® UDS100
New
Pipette Calibration System
Artel PCS®
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.